Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
AVEO Pharmaceuticals Inc. maintains 1 pending office action in its current prosecution profile. This action is being handled by a distinct examiner. The busiest examiner identified in the data is HOLTZMAN, KATHERINE ANN, who accounts for 1 pending office action. The prosecution effort for this portfolio is currently concentrated on the pending matter under the review of the examiner. With the matter assigned to this person, the company can direct all its attention to the specific issues raised by HOLTZMAN, KATHERINE ANN. This point of contact streamlines the prosecution process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLTZMAN, KATHERINE ANN | 1 | 65.7% | +58.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667500 | COMBINATION THERAPY FOR TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667500 | COMBINATION THERAPY FOR TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18667500 | COMBINATION THERAPY FOR TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | — | §101§102§103§112 | Non-Final OA | — | Pending | May 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial